Rheumatoid Arthritis

17 competing products in clinical development for Rheumatoid Arthritis.

Pipeline by Phase

Pre-clinical2

Phase 12

Phase 21

Phase 311

Approved1

All Products (17)

Product	Company	Stage	Status	Hype
Baricitinib + TNF Inhibitor	Eli Lilly	Approved	Completed	85
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid	Eli Lilly	Phase 3	Completed	77
LY2127399	Eli Lilly	Phase 3	Terminated	77
CT-P17 SC AI (adalimumab)	Celltrion	Phase 3	Completed	77
CT-P13 + Remicade	Celltrion	Phase 3	Completed	77
CT-P47 + EU-approved RoActemra	Celltrion	Phase 3	Completed	77
Infliximab	Celltrion	Phase 3	Completed	77
CT-P10 + Rituxan + MabThera	Celltrion	Phase 3	Completed	77
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)	Celltrion	Phase 3	UNKNOWN	77
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 3	Completed	77
CT-P17 SC + Humira SC	Celltrion	Phase 3	Completed	77
Infliximab	Celltrion	Phase 3	Completed	77
Tc99m tilmanocept	Navidea Biopharmaceuticals	Phase 2	Completed	44
Rituximab, MTX, folic acid	Celltrion	Phase 1	Completed	33
rituximab	Celltrion	Phase 1	Completed	33
Remsima IV + Remsima SC	Celltrion	Pre-clinical	Recruiting	23
Adalimumab	Celltrion	Pre-clinical	UNKNOWN	23